Corvus Pharmaceuticals, Inc. CRVS

Valuation picture for Corvus Pharmaceuticals is under scrutiny as shares retreat about 19% in a month and 13% in 3 months from an $11.80 close. Year-to-date gains remain robust (roughly 61%), and 1-year total shareholder return sits near 79% with longer-term momentum (3-year TSR about 7x). A crowd-sourced view sets fair value around $42, implying substantial upside if Soq uelitinib in peripheral T-cell lymphoma reaches late-stage success and profitability materializes, discounted at 7.17%. The story shifts from a single-asset company to a potential oncology franchise, contingent on late-stage approvals and revenue ramp. Risks include reliance on loss-making, pre-revenue programs and potential dilutive funding if timelines slip. Despite upside, valuation hinges on execution and financing; readers are urged to test assumptions themselves. Upside hinges on Soquelitinib success and funding, so sentiment could shift moderately but fundamentals depend on execution.

Corvus Pharmaceuticals announces publication of final Phase 1 data from Soquelitinib Phase 1/1b T cell lymphoma trial in Blood journal. Phase 1 data publication advances soquelitinib development and may moderately shift company trajectory.

Corvus Pharmaceuticals advances clinical drug development with updates that heighten investor interest in its pipeline. Clinical updates strengthen the company's development prospects and market position.

Corvus Pharmaceuticals (CRVS) released its Q2 2026 earnings call transcript detailing financial results, operational updates and forward outlook. Earnings call provides quarterly results and guidance that can moderately shift near-term investor sentiment and valuation.

Corvus Pharmaceuticals highlighted advancements in Soquelitinib during its Q2 2026 earnings call. Soquelitinib advancement represents major pipeline progress that can shift company trajectory.

Corvus Pharmaceuticals, Inc. held its Q2 2026 earnings call. Q2 2026 earnings call delivers financial updates that may moderately influence stock performance and outlook.

Corvus Pharmaceuticals discussed Q2 financial results, pipeline progress and upcoming milestones during its earnings call. Q2 earnings call supplied operational and clinical updates that may moderately influence near-term investor views.

Corvus Pharmaceuticals reported second quarter 2026 financial results and issued a business update. Quarterly financial reporting and business updates supply data on cash runway and operations that can shift near-term investor views.

Corvus Pharmaceuticals awaits pivotal Soquelitinib clinical data releases that may draw merger and acquisition interest from larger players. Pivotal drug data releases combined with M&A speculation can materially alter company valuation and trajectory.

Corvus Pharmaceuticals makes additional investment in Angel Pharmaceuticals to advance Soquelitinib development in China. Investment targets China-specific Soquelitinib progress, affecting regional positioning without broad global trajectory shift.

Boxer Capital invested $18 million in Corvus Pharmaceuticals, signaling strong confidence in the biotech company's upcoming development phase. The $18 million investment by Boxer Capital strengthens Corvus Pharmaceuticals' funding and market sentiment around its next development phase.

Corvus Pharmaceuticals presented Phase 1 clinical data for soquelitinib in atopic dermatitis at the Society for Investigative Dermatology Annual Meeting. Phase 1 data presentation signals pipeline progress in atopic dermatitis, likely influencing investor sentiment moderately without transformative effects.

Corvus Pharmaceuticals returns to losses and announces new shelf offering, potentially weakening the investment case amid financial strain and dilution risks. Return to losses highlights financial weakness while shelf offering signals potential dilution, significantly pressuring stock performance and investor sentiment.

Corvus Pharmaceuticals provided a business update and reported first quarter 2026 financial results. Quarterly financial results and business update influence financial performance and market sentiment but remain routine without transformative details.

Corvus Pharmaceuticals to host investor and analyst meeting on May 14, 2026, highlighting Soquelitinib data presented at the Society for Investigative Dermatology Annual Meeting. Investor meeting to highlight upcoming Soquelitinib clinical data at SID could moderately influence market sentiment and biotech trajectory.

Corvus Pharmaceuticals, Inc. (CRVS) released Q4 2025 earnings call summary covering financial results, clinical pipeline updates, and strategic outlook. Q4 2025 earnings call summary reveals financial performance and pipeline progress pivotal to investor sentiment and stock trajectory.

Corvus Pharmaceuticals (CRVS) Q4 2025 earnings call transcript released, covering financial results, pipeline updates, and forward guidance. Q4 earnings transcript discloses financial outcomes, clinical progress, and strategic plans directly influencing CRVS stock trajectory and investor outlook.

Corvus Pharmaceuticals Inc (CRVS) Q4 2025 earnings call highlights strategic advances amid challenges, covering key financials, pipeline progress, and future outlook. Strategic advances highlighted in Q4 2025 earnings call represent major moves poised to alter CRVS trajectory and boost investor sentiment.

Corvus Pharmaceuticals released Q4 earnings call highlights covering financial results, clinical trial updates, and strategic priorities. Q4 earnings highlights provide updates on finances and pipeline that moderately influence investor sentiment and stock trajectory.

Corvus Pharmaceuticals, Inc. (CRVS) released its Q4 earnings snapshot. Q4 earnings snapshot impacts financial performance and market sentiment.

Corvus Pharmaceuticals provided a business update and reported fourth quarter and full-year 2025 financial results. Business updates and financial results for a biotech firm can moderately influence stock performance and investor views on pipeline advancement.

Corvus Pharmaceuticals highlights soquelitinib pipeline progress and plans Phase II atopic dermatitis trial initiation in 2026. Pipeline advancement toward Phase II atopic dermatitis trial in 2026 moderately bolsters product development prospects and investor sentiment.

Corvus Pharmaceuticals, Inc. (CRVS) is highlighted as one of three rapid-growth stocks poised for momentum in 2026. The company is expected to benefit from its innovative pipeline and strategic initiatives, which could enhance its market position and attract investor interest. Analysts suggest that CRVS's focus on advancing its drug development programs may lead to significant growth opportunities in the coming years. The company's strategic initiatives and innovative pipeline are likely to significantly impact its future performance and market position.

Corvus Pharmaceuticals, Inc. (CRVS) experienced a remarkable 209% stock rally over the past month, driven by positive developments in its clinical trials and strategic partnerships. The company's focus on innovative cancer therapies has garnered investor interest, particularly following promising results from its lead drug candidate. Analysts are optimistic about the potential for future growth, citing the company's strong pipeline and recent advancements in research. This surge in stock price reflects heightened market confidence in Corvus's ability to deliver on its therapeutic promises and capitalize on emerging opportunities in the oncology sector. Significant advancements in clinical trials and strategic partnerships are likely to alter the company's trajectory and investor sentiment.

Corvus Pharmaceuticals, Inc. (CRVS) has experienced a remarkable increase of 211.80% in its stock price over the past week, driven by positive developments in its clinical trials and investor interest. The surge reflects heightened market enthusiasm for the company's innovative therapies targeting cancer treatment. Analysts are closely monitoring the situation as the company progresses with its research and potential product launches, which could further influence its market position and investor sentiment. The significant stock price increase is likely tied to major developments in clinical trials that could alter the company's trajectory.

Wall Street analysts project a potential surge of 25.29% for Corvus Pharmaceuticals, Inc. (CRVS) based on recent developments and market sentiment. The company's strategic initiatives and upcoming product launches are expected to positively influence its stock performance. Investors are encouraged to consider these factors before making investment decisions. Significant strategic initiatives and market sentiment shifts are likely to impact Corvus's future performance.

Corvus Pharmaceuticals, Inc. (CRVS) experienced a dramatic 212% surge in stock price following the announcement of positive results from a clinical study on its eczema therapy. The study demonstrated significant efficacy in treating the condition, leading to heightened investor interest and optimism about the company's future prospects in dermatological treatments. This breakthrough could position Corvus favorably in a competitive market, potentially attracting partnerships and further investment. The positive study results could significantly enhance Corvus's market position and investor sentiment, indicating a major strategic advancement.

Corvus Pharmaceuticals, Inc. (CRVS) shares surged 211.8% following an upsized equity raise aimed at funding the Phase 2 clinical trials for Soquelitinib, a treatment for various cancers. The company plans to utilize the raised capital to advance its clinical development and enhance its market position. Investors reacted positively to the news, reflecting increased confidence in the company's future prospects. The upsized equity raise and Phase 2 plans for Soquelitinib represent significant strategic moves that could alter the company's trajectory and investor sentiment.

Corvus Pharmaceuticals, Inc. has successfully closed an upsized public offering of common stock, raising approximately $201 million in gross proceeds. The offering included the full exercise of the underwriters’ option to purchase additional shares, indicating strong investor interest and confidence in the company's prospects. The significant capital raised is likely to enhance the company's financial position and support future strategic initiatives.

Corvus Pharmaceuticals, Inc. (CRVS) reached an all-time high following positive results from its eczema trial. The trial demonstrated significant efficacy in treating the condition, leading to increased investor confidence and market interest in the company's future prospects. This milestone is expected to enhance Corvus's position in the competitive pharmaceutical landscape. Positive trial results are likely to significantly impact future performance and investor sentiment.